ublituximab + lenalidomide

**Ublituximab + lenalidomide** is an investigational combination regimen comprising two drugs: - **Ublituximab**: a glycoengineered anti-CD20 monoclonal antibody that targets CD20 antigen on B lymphocytes, leading to enhanced antibody-dependent cellular cytotoxicity (ADCC) and direct B-cell lysis. - **Lenalidomide**: an immunomodulatory small molecule that binds cereblon, modulates E3 ubiquitin ligase activity, enhances immune effector cell function, inhibits angiogenesis, and exerts antineoplastic effects via degradation of IKAROS and AIOLOS transcription factors. This combination is being explored for the treatment of B-cell malignancies, especially relapsed or refractory non-Hodgkin lymphomas such as follicular lymphoma and chronic lymphocytic leukemia. Primary mechanism is synergistic killing of malignant B cells via both direct lysis (ublituximab) and immune modulation (lenalidomide). Developers include TG Therapeutics (ublituximab) and various sponsors for lenalidomide, originally developed by Celgene (now Bristol Myers Squibb).